Lucia Masarova/X
Sep 5, 2025, 12:18
Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg’s Efficacy for Essential Thrombocythemia
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | POSTER
Lucia Masarova, MD Anderson Cancer Center
Presents results from the phase III SURPASS-ET trial of ropeginterferon alfa-2b (n=91) vs anagrelide (n=83) in patients with HR Essential Thrombocythemia who are resistant or intolerant to hydroxyurea.
Ropeg showed superior efficacy over anagrelide (RR, 42.9% vs 6.0%, P=0.0001) and demonstrated a favorable safety profile.”
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Nov 10, 2025, 10:16Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
-
Nov 10, 2025, 10:15Laurent Bertoletti Invites You to the Joint INNOVTE and GITA Meeting on Hormones and Thrombosis
-
Nov 10, 2025, 10:15Christopher Cannon: DOAC Monotherapy Wins Again
-
Nov 10, 2025, 10:14Marieke Kruip on Sex differences in Outcomes of VKA Treatment in Patients with Mechanical Heart Valve
-
Nov 10, 2025, 10:14Ana Paula Lacombe: From Research to Bedside, Innovation in Stroke Care is Moving Fast!
-
Nov 10, 2025, 10:13Jan Sloves: Understanding Iliofemoral DVT – What You Can’t Afford to Miss
-
Nov 10, 2025, 10:12Mohamed Rawy Shares a Comprehensive Guide For Anticoagulation
-
Nov 10, 2025, 10:10Marc Carrier: Proud to Share the Results of the WAVe Study
-
Nov 10, 2025, 10:07Frederik Denorme – The New PI at the Laboratory of Cell Biology and Histology at University of Antwerp